These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 32839463)

  • 1. Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate.
    Pandey A; Stawiski EW; Durinck S; Gowda H; Goldstein LD; Barbhuiya MA; Schröder MS; Sreenivasamurthy SK; Kim SW; Phalke S; Suryamohan K; Lee K; Chakraborty P; Kode V; Shi X; Chatterjee A; Datta K; Khan AA; Subbannayya T; Wang J; Chaudhuri S; Gupta S; Shrivastav BR; Jaiswal BS; Poojary SS; Bhunia S; Garcia P; Bizama C; Rosa L; Kwon W; Kim H; Han Y; Yadav TD; Ramprasad VL; Chaudhuri A; Modrusan Z; Roa JC; Tiwari PK; Jang JY; Seshagiri S
    Nat Commun; 2020 Aug; 11(1):4225. PubMed ID: 32839463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ELF3 suppresses gallbladder cancer development through downregulation of the EREG/EGFR/mTOR complex 1 signalling pathway.
    Nakamura T; Nishikawa Y; Shiokawa M; Takeda H; Yokode M; Matsumoto S; Muramoto Y; Ota S; Yoshida H; Okada H; Kuwada T; Marui S; Matsumori T; Maruno T; Uza N; Kodama Y; Hatano E; Seno H
    J Pathol; 2023 Sep; 261(1):28-42. PubMed ID: 37345534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ELF3 promotes gemcitabine resistance through PKMYT1/CDK1 signaling pathway in gallbladder cancer.
    Yang L; Wang H; Guo M; He M; Zhang W; Zhan M; Liu Y
    Cell Oncol (Dordr); 2023 Aug; 46(4):1085-1095. PubMed ID: 36988891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ELF3, ELF5, EHF and SPDEF Transcription Factors in Tissue Homeostasis and Cancer.
    Luk IY; Reehorst CM; Mariadason JM
    Molecules; 2018 Aug; 23(9):. PubMed ID: 30200227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of MAP kinase pathways as therapeutic targets in gallbladder carcinoma using targeted parallel sequencing.
    Li M; Chen L; Qu Y; Sui F; Yang Q; Ji M; Shi B; Chen M; Hou P
    Oncotarget; 2017 May; 8(22):36319-36330. PubMed ID: 28422736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A transcriptional repressive role for epithelial-specific ETS factor ELF3 on oestrogen receptor alpha in breast cancer cells.
    Gajulapalli VN; Samanthapudi VS; Pulaganti M; Khumukcham SS; Malisetty VL; Guruprasad L; Chitta SK; Manavathi B
    Biochem J; 2016 Apr; 473(8):1047-61. PubMed ID: 26920025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and Pathological Characteristics of
    Frank R; Scheffler M; Merkelbach-Bruse S; Ihle MA; Kron A; Rauer M; Ueckeroth F; König K; Michels S; Fischer R; Eisert A; Fassunke J; Heydt C; Serke M; Ko YD; Gerigk U; Geist T; Kaminsky B; Heukamp LC; Clement-Ziza M; Büttner R; Wolf J
    Clin Cancer Res; 2018 Jul; 24(13):3087-3096. PubMed ID: 29615460
    [No Abstract]   [Full Text] [Related]  

  • 8. Elf3 drives β-catenin transactivation and associates with poor prognosis in colorectal cancer.
    Wang JL; Chen ZF; Chen HM; Wang MY; Kong X; Wang YC; Sun TT; Hong J; Zou W; Xu J; Fang JY
    Cell Death Dis; 2014 May; 5(5):e1263. PubMed ID: 24874735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells.
    Yeung TL; Leung CS; Wong KK; Gutierrez-Hartmann A; Kwong J; Gershenson DM; Mok SC
    Oncotarget; 2017 Mar; 8(10):16951-16963. PubMed ID: 28199976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. aPKCι promotes gallbladder cancer tumorigenesis and gemcitabine resistance by competing with Nrf2 for binding to Keap1.
    Tian L; Lu Y; Yang T; Deng Z; Xu L; Yao W; Ma C; Li X; Zhang J; Liu Y; Wang J
    Redox Biol; 2019 Apr; 22():101149. PubMed ID: 30822690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcription factor 4 expression and correlation with tumor progression in gallbladder cancer.
    Neogi K; Tewari M; Singh AK; Sharma K; Tej GNVC; Verma SS; Gupta SC; Nayak PK
    J Cancer Res Ther; 2022; 18(3):668-676. PubMed ID: 35900539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ELF3 is an antagonist of oncogenic-signalling-induced expression of EMT-TF ZEB1.
    Liu D; Skomorovska Y; Song J; Bowler E; Harris R; Ravasz M; Bai S; Ayati M; Tamai K; Koyuturk M; Yuan X; Wang Z; Wang Y; Ewing RM
    Cancer Biol Ther; 2019; 20(1):90-100. PubMed ID: 30148686
    [No Abstract]   [Full Text] [Related]  

  • 13. The genomic landscape of hepatoblastoma and their progenies with HCC-like features.
    Eichenmüller M; Trippel F; Kreuder M; Beck A; Schwarzmayr T; Häberle B; Cairo S; Leuschner I; von Schweinitz D; Strom TM; Kappler R
    J Hepatol; 2014 Dec; 61(6):1312-20. PubMed ID: 25135868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma.
    Goeman F; De Nicola F; Scalera S; Sperati F; Gallo E; Ciuffreda L; Pallocca M; Pizzuti L; Krasniqi E; Barchiesi G; Vici P; Barba M; Buglioni S; Casini B; Visca P; Pescarmona E; Mazzotta M; De Maria R; Fanciulli M; Ciliberto G; Maugeri-Saccà M
    J Thorac Oncol; 2019 Nov; 14(11):1924-1934. PubMed ID: 31323387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear factor erythroid 2-related factor 2 and β-Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications.
    Tao J; Krutsenko Y; Moghe A; Singh S; Poddar M; Bell A; Oertel M; Singhi AD; Geller D; Chen X; Lujambio A; Liu S; Monga SP
    Hepatology; 2021 Aug; 74(2):741-759. PubMed ID: 33529367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. E26 transformation (ETS)‑specific related transcription factor‑3 (ELF3) orchestrates a positive feedback loop that constitutively activates the MAPK/Erk pathway to drive thyroid cancer.
    Chen H; Chen W; Zhang X; Hu L; Tang G; Kong J; Wang Z
    Oncol Rep; 2019 Jan; 41(1):570-578. PubMed ID: 30365150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. E74-Like Factor 3 Is a Key Regulator of Epithelial Integrity and Immune Response Genes in Biliary Tract Cancer.
    Suzuki M; Saito-Adachi M; Arai Y; Fujiwara Y; Takai E; Shibata S; Seki M; Rokutan H; Maeda D; Horie M; Suzuki Y; Shibata T; Kiyono T; Yachida S
    Cancer Res; 2021 Jan; 81(2):489-500. PubMed ID: 33293429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. E74 like ETS transcription factor 3 (ELF3) is a negative regulator of epithelial- mesenchymal transition in bladder carcinoma.
    Gondkar K; Patel K; Krishnappa S; Patil A; Nair B; Sundaram GM; Zea TT; Kumar P
    Cancer Biomark; 2019; 25(2):223-232. PubMed ID: 31104013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ETS transcription factor ESE1/ELF3 orchestrates a positive feedback loop that constitutively activates NF-κB and drives prostate cancer progression.
    Longoni N; Sarti M; Albino D; Civenni G; Malek A; Ortelli E; Pinton S; Mello-Grand M; Ostano P; D'Ambrosio G; Sessa F; Garcia-Escudero R; Thalmann GN; Chiorino G; Catapano CV; Carbone GM
    Cancer Res; 2013 Jul; 73(14):4533-47. PubMed ID: 23687337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer.
    Shibata T; Kokubu A; Gotoh M; Ojima H; Ohta T; Yamamoto M; Hirohashi S
    Gastroenterology; 2008 Oct; 135(4):1358-1368, 1368.e1-4. PubMed ID: 18692501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.